Stem Cell Therapeutics Corp.

Stem Cell Therapeutics Corp.

August 11, 2009 10:48 ET

Stem Cell Therapeutics Corp. Announces Enrollment of First Patient in the modified REGENESIS Phase IIb Stroke Trial

CALGARY, ALBERTA--(Marketwire - Aug. 11, 2009) - Stem Cell Therapeutics Corp. ("SCT" or the "Company") (TSX VENTURE:SSS) is pleased to announce the enrollment of the first patient in its modified REGENESIS Phase IIb acute ischemic stroke trial. The modified REGENESIS trial is a double-blind, randomized, placebo-controlled Phase IIb clinical trial for SCT's lead program, NTx®-265, for the treatment of acute ischemic stroke. This first patient was enrolled by the clinical team of Dr. Vijaya Pamidimukkala from the Lalitha Super Specialties Hospital Pvt Ltd in Guntur, Hyderabad, A.P. Co-lead investigators for the modified REGENESIS Phase IIb trial are Dr. Steven C. Cramer of the University of California, Irvine, and Dr. Michael D. Hill of the Foothills Hospital at the University of Calgary.

Dr. Alan Moore, President and CEO, commented as follows:

"We are very happy to have begun recruiting the modified Phase IIb REGENESIS stroke trial. We have great expectations that this Phase IIb acute ischemic stroke trial will continue to build upon the positive clinical data available to-date, specifically the exciting results highlighted by the meta-analysis as announced on July 27th. Trial completion for the modified Phase IIb clinical stroke trial is anticipated for the end of calendar year 2009, allowing top-line data to be available by the end of Q1 09."

The modified REGENESIS Phase IIb acute ischemic stroke trial will be a multi-site trial, projected to enroll 128 patients at sites located in India, Canada and the U.S.

Additionally, the early warrant exercise incentive program which was announced on July 8th has since closed and is no longer available.

About Stem Cell Therapeutics Corp.: Stem Cell Therapeutics Corp. is a Canadian public biotechnology company (TSX VENTURE:SSS) focused on the development and commercialization of drug-based therapies to treat central nervous system diseases. SCT is a leader in the development of therapies that utilize drugs to stimulate a patient's own resident stem cells. The Company's programs aim to repair brain and nerve function lost due to disease or injury. The Company's extensive patent portfolio of owned and licensed intellectual property supports the potential expansion into future clinical programs in numerous neurological diseases such as traumatic brain injury, multiple sclerosis, Huntington's disease, Alzheimer's disease, and ALS.

These securities have not been registered under the United States Securities Act of 1933, as amended, or the securities laws of any state, and may not be offered or sold within the United States or to, or for the account or benefit of U.S. persons unless an applicable exemption from U.S. registration requirements is available.

Except for historical information, this press release may contain forward-looking statements, which reflect the Company's current expectation regarding future events. These forward-looking statements involve risk and uncertainties, which may cause but are not limited to, changing market conditions, the successful and timely completion of clinical studies, the establishment of corporate alliances, the impact of competitive products and pricing, new product development, uncertainties related to the regulatory approval process and other risks detailed from time to time in the Company's ongoing quarterly and annual reporting.

Neither TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in the policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this release.

Contact Information